Bradsaúde’s Atlântica Partners With Fleury for Outpatient Oncology Joint Venture

• Bradsaúde’s indirectly controlled Atlântica signed a binding memorandum with Fleury on November 10, 2026, to establish outpatient oncology venture FleuryOnco.
• Fleury will own 50.1% and oversee medical, operational and commercial management; Atlântica will hold 49.9%.
• The initial phase calls for BRL 72 million in investment, with seven units planned by the end of 2027.
• FleuryOnco will operate through Fleury Oncologia in São Paulo and Onco One nationwide.
• Closing remains subject to definitive agreements and customary conditions, including regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bradsaude SA published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.